DIMERIX LIMITED — Investor Presentation 2026

Mar 15, 2026

For Immediate Release

==> picture [213 x 47] intentionally omitted <==

DIMERIX TO PRESENT AT EUROZ HARTLEYS INSTITUTIONAL CONFERENCE 2026

MELBOURNE, Australia, 16 March 2026: Dimerix Limited (ASX: DXB), a biopharmaceutical company with a Phase 3 clinical asset in kidney disease, is pleased to advise that CEO and Managing Director, Dr Nina Webster, will be presenting at the Euroz Hartleys Institutional Conference on Rottnest Island from 17-19 March 2026.

A copy of the presentation is attached.

Dr Webster will present an update on the following:

• Phase 3 global clinical trial in FSGS kidney disease

• Next steps, including the planned blinded statistical powering review

• Commercial partnering status

• Company growth strategy

Further information about the study can be found on ClinicalTrials.gov (Study Identifier: NCT05183646) or Australian New Zealand Clinical Trials Registry (ANZCTR) (Study Identifier ACTRN12622000066785).

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster Jane Lowe Dimerix Limited IR Department Chief Executive Officer & Managing Director Tel: +61 411 117 774 Tel: +61 1300 813 321 E: jane.lowe@irdepartment.com.au E: investor@dimerix.com Follow Dimerix on LinkedIn and X

Authorised for lodgement by the Board of Dimerix

—END—

About Dimerix Limited

DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. DMX-200 is protected by granted patents in various territories until 2032, with patent applications submitted globally that may extend patent protection to 2045, in addition to Orphan Drug Designation granted in the United States, Europe, UK and Japan[1] . For more information, please visit the company’s website at www.dimerix.com and follow on X and LinkedIn.

==> picture [471 x 60] intentionally omitted <==

----- Start of picture text -----

Dimerix is a biopharmaceutical Dimerix HQ
425 Smith St, Fitzroy 3065
company developing innovative new
Victoria, Australia
therapies in areas with unmet
T. 1300 813 321
medical needs.
E. info@dimerix.com
----- End of picture text -----

About FSGS

FSGS is a rare, serious kidney disorder characterised by progressive scarring (sclerosis) in parts of the glomeruli—the kidney’s filtering units. This scarring leads to proteinuria, progressive loss of kidney function, and often end-stage renal disease. FSGS is increasingly understood to have an inflammatory component, with monocyte and macrophage activation contributing to glomerular injury. In the United States, more than 40,000 people are estimated to be living with FSGS, including both adults and children.[2] There are no therapies specifically approved for FSGS in the U.S., and disease management relies on non-specific immunosuppressive and supportive therapies. In patients with progressive or treatment-resistant FSGS, the average time from diagnosis to end-stage kidney disease can be as short as five years. Even among those who undergo kidney transplantation, disease recurrence occurs in up to 60% of cases,[3] underscoring the urgent need for new, disease-modifying treatments.

About FSGS Phase 3 Study

The ACTION3 Phase 3 study is a pivotal Phase 3, multi-centre, randomised, double-blind, placebocontrolled study of the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of a blood pressure medication known as an angiotensin II receptor blocker (ARB). Once the ARB dose is stable, patients are then randomised to receive either DMX-200 (120 mg capsule, twice daily) or placebo for a 2-year treatment period.

The single Phase 3 trial in FSGS patients is designed to capture evidence of proteinuria reduction and kidney function (eGFR slope) during the trial, aimed at generating sufficient evidence to support marketing approval.

Dimerix Forward Looking Statement

This release includes forward-looking statements that are subject to risks and uncertainties. Although management believes that the expectations reflected in the forward-looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, including but not limited to those factors outlined in the most recent Dimerix Limited Annual Report.

References

1 ASX releases: 14 December 2015, 21 November 2018, 07 June 2021, 30 September 2025

2 Nephcure FSGS Facts (https://nephcure.org/)

3 Front. Immunol., (July 2019) | https://doi.org/10.3389/fimmu.2019.01669

==> picture [541 x 281] intentionally omitted <==

==> picture [346 x 76] intentionally omitted <==

(ASX:DXB)

Developing new therapies to treat inflammatory causes of kidney disease with unmet clinical needs

Euroz Hartleys

Institutional Conference

Rottnest Island – 17-19 March 2026

Authorised for lodgement by the Board of the Company

Forward looking statements

This presentation includes forward-looking statements that are subject to risks and uncertainties. Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, Dimerix can give no assurance that these expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking statements.

Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, results of clinical trials, contractual risks, risks associated with patent protection, future capital needs or other general risks or factors, including but not limited to those factors outlined in the most recent Dimerix Limited Annual Report.

2

Overview Phase 3 Global Opportunity

FSGS indication

Phase 3 trial

Reduced risk

recruitment Proteinuria endpoint is a rare disease complete in passed blinded that causes scarring trial of DMX-200 in interim (futility) of the kidney, focal segmental assessment (March leading to glomerulosclerosis 2024)[1] irreversible damage[2] (FSGS)

No approved Orphan drug 4 commercial treatments designations partners specifically for regulatory, DMX-200 licensed FSGS: marketing in USA, Europe, damage can lead to exclusivity and Canada, Australia, dialysis, transplant pricing benefits in NZ, Japan and GCC[4] or death[2] key territories[3]

up to $1.4 billion

in total development and sales milestone payments plus royalties[3]

==> picture [883 x 153] intentionally omitted <==

==> picture [137 x 31] intentionally omitted <==

1. ASX release ASX release 11 March 2024 2. Guruswamy Sangameswaran KD, Baradhi KM. Focal Segmental Glomerulosclerosis (July 2021), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/; 3. ASX releases: 14 December 3 2015, 21 November 2018, 07 June 2021; 4. ASX release 05 October 2023, 27 May 2024, 07 January 2025 and 01 May 2025

Cycle of damage :

What is FSGS?

Focal = some Segmental = sections Glomerulo = of the kidney filtering units Sclerosis = are scarred

==> picture [137 x 31] intentionally omitted <==

==> picture [12 x 540] intentionally omitted <==

in glomerular diseases

Existing blood pressure medication

==> picture [560 x 343] intentionally omitted <==

----- Start of picture text -----

Glomeruli exposed to stress DMX-200
from high blood pressure
1
High blood pressure
causes hyperfiltration
within filter units
2
(glomeruli) of the
Constant pressure
kidney [1]
causes inflammation of
glomerulus and influx
of inflammatory
immune cells
Fewer kidney cells drive higher
blood pressure and further
hyperfiltration and inflammation
As cells die, glomerular become scarred and
protein leaks into the urine ( proteinuria )
3
Pro-inflammatory
environment drives
sclerosis and fibrosis
that is permanent
and non-reversable
----- End of picture text -----

1. Lewis, E. J. et al. (2001), New Engl J Medicine 345, 851–860

4

Inter retin p g proteinuria as a surrogate endpoint

Proteinuria is the quantity of protein in the urine

A healthy kidney is a good filter and allows little to no protein into the urine[1]

==> picture [225 x 9] intentionally omitted <==

----- Start of picture text -----

Inside a healthy kidney Inside a damaged kidney
----- End of picture text -----

==> picture [278 x 135] intentionally omitted <==

• When kidneys are damaged, protein can leak into the urine causing proteinuria

• Proteinuria represents an important early marker of kidney function[2]

==> picture [459 x 320] intentionally omitted <==

----- Start of picture text -----

Proteinuria as a predictor of kidney disease [3]
Dip test uPCR g/g
Neg <0.13 normal
Trace 0.13
+ 0.62
0.88 proteinuric
++ 1.24
Minimal uPCR for ACTION3 inclusion
+++ 2.30
++++ >3.09 nephrotic
NORMAL
MICROALBUMINURIA
HEAVY ALBUMINURIA
----- End of picture text -----

Proteinuria is typically less variable and easier to measure than eGFR[4]

==> picture [137 x 31] intentionally omitted <==

1.Guruswamy Sangameswaran KD, Baradhi KM. Focal Segmental Glomerulosclerosis (July 2021), online: https://www.ncbi.nlm.nih.gov/books/NBK532272/; 2. Nephcure FSGS living with the disease (2024) at https://nephcure.org/livingwithkidneydisease/ns-and-other-glomerular-diseases/understanding-fsgs/ ; 3. Adapted from graphics prepared by Renal Unit at the Royal Infirmary of Edinburgh and the University of Edinburgh; 4. PARASOL outcomes 2024, a working group made up of: NephCure, ISGD, NKF, KHI are co-sponsors of the project, FDA and EMA involvement, University of Michigan is data coordinating center, Industry invited as participants

5

Measurin eGFR as a surro ate end oint g g p

Estimated glomerular filtration rate (eGFR) is the measurement of the kidney filtration rate

==> picture [372 x 256] intentionally omitted <==

Treatments, such as DMX-200, aim to bring the FSGS slope back up:

• can add years to the life of the kidney

• • potential to delay dialysis and/or kidney transplant

• Kidney function is measured using the estimated rate of blood filtered by the kidney per minute (millilitres per minute)

• eGFR slope naturally declines as we age[1]

• In FSGS patients, kidney function is decreasing rapidly

==> picture [137 x 31] intentionally omitted <==

1. National Kidney Foundation: Estimated Glomerular Filtration Rate (eGFR): https://www.kidney.org/atoz/content/gfr

6

DMX-200 – inflammatory modulator

A CCR2 inhibitor working synergistically alongside the current standard of care (AT1R blocker): G protein-coupled receptor (GPCR)

==> picture [863 x 204] intentionally omitted <==

----- Start of picture text -----

Commercial manufacturing sites
established in USA [3]
----- End of picture text -----

==> picture [137 x 31] intentionally omitted <==

1. ASX release and investor presentation 29Jul20 and ASX release 11Mar24 BID: bis in die/ twice a day

7

DMX-200: Phase 2 met primary endpoint

==> picture [928 x 397] intentionally omitted <==

----- Start of picture text -----

Clinically encouraging outcomes achieved for patients, [1,2] with no safety concerns noted [3]
Average reduction of 17% in proteinuria after 16 weeks
treatment on DMX-200 versus placebo [3]
“Any reduction in proteinuria
could yield years of
preserved native kidney E F F I C A C Y S A F E T Y
function and delay the onset
of kidney failure and its • 86% of patients • No safety concerns –
attendant morbidity and demonstrated reduced reduced development
mortality” proteinuria risk
Kidney survival study – Troost et al,
August 2020 [2] • DMX-200 reduced
inflammatory biomarker
by 39% vs placebo
----- End of picture text -----

==> picture [137 x 31] intentionally omitted <==

PCR = protein creatinine ratio; ARB = angiotensin receptor blocker; 1. Trachtman, et al., 2018. J Amer Soc Nephrology 29(11):2745-2754; 2. Troost JP et al (August 2020); doi.org/10.1053/j.ajkd.2020.04.014; 3. Repeated measures mixed model analysis per protocol; top line data was reported as grouped analysis on 29 July 2020, study not designed for statistical significance;

8

European Renal Association Posters 2025

==> picture [183 x 93] intentionally omitted <==

phase 3 clinical trial

A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB (n=≥286)

==> picture [960 x 296] intentionally omitted <==

----- Start of picture text -----

Background Phase 3 Trial Timeline Open Label Extension
Successful interim analysis [1] Planned blinded Final analysis
( using statistical measure ) ≥286 patients @
statistical powering
72 patients @ 35 weeks 104 weeks
review [2]
(% change in uPCR) (uPCR/eGFR) [3]
• Patients recruited, then screened
and stabilised on background
medications ARB + placebo
DMX-200
• Patients randomised to receive 72/76 (95%) [4] patients
drug or placebo enrolled in open label
extension study to date
• DXB remains blinded at all times ARB + DMX-200
during study
planned blinded statistical review of final
endpoints, assuming FDA alignment [2]
ACTION3 Study End
----- End of picture text -----

==> picture [137 x 31] intentionally omitted <==

1. Blinded interim Phase 3 analysis data does not guarantee a statistically significant outcome at the end of the trial, ASX release 11 March 2024; 2. The potential for accelerated (or conditional) approval submissions,

following the second blinded review and any potential unblinding, will be assessed based on discussions with the appropriate regulatory authorities such as the FDA in the US and blinded statistical powering outcomes; 3. Regardless of any accelerated (conditional) approval potential, ACTION3 study will complete full 2 year analysis and regulatory submission for potential traditional (full) approval; 4. number and % of eligible patients who have completed 2 years treatment as at 13 March 2026; ARB = angiotensin receptor blocker; uPCR = urinary proteinuria; eGFR = estimated glomerular filtration rate (kidney function);

9

Adult patient recruitment by territory

==> picture [233 x 42] intentionally omitted <==

----- Start of picture text -----

Trial designed for potential
approval globally
----- End of picture text -----

==> picture [220 x 110] intentionally omitted <==

----- Start of picture text -----

Recruitment
completed
(adult population) [1]
----- End of picture text -----

==> picture [241 x 246] intentionally omitted <==

----- Start of picture text -----

333
Adult patients recruited,
randomised and dosed
(target ≥286) [2]
6
Paediatric patients recruited,
randomised and dosed [2]
----- End of picture text -----

==> picture [492 x 11] intentionally omitted <==

----- Start of picture text -----

Latin America Asia Pacific US / Europe
----- End of picture text -----

==> picture [137 x 31] intentionally omitted <==

==> picture [295 x 15] intentionally omitted <==

----- Start of picture text -----

1. ASX release 15 December 2025; 2. Final numbers of adult patients, ASX release 10 March 2026;
paediatric patients will continue to recruit, and will not impact final analysis timelines
----- End of picture text -----

10

Evolution of FSGS landscape & ACTION3 study

Oct 2023: Partnered with Advanz for UK, EU, Sep 2024: First ACTION3 patient Canada and ANZ completes 2 years and enters May 2025: partnered with Open Label Extension Study Amicus for USA Dec 2025: n = 286 adults Nov 2023: IND randomised and dosed June 2024 – Partnered opened in China with Taiba for GCC + Iraq Jul 2022: First ACTION3 January 2025 – Partnered Mar 2026: final Phase 3 clinical study Jul 2023: First 72 Mar 2024 – ACTION3 with FUSO for Japan Oct 2025: 21st and adult randomised patient randomised Phase 3 clinical trial Jul 2024 and dosed n = 333 patients randomised passed interim opened to paediatric April 2025: 20th final country added - Türkiye opens analysis on first 72 enrolment 12-17 yrs recruiting country patients at 35 weeks added - Japan H2 2022 H1 2023 H2 2023 H1 2024 H2 2024 H1 2025 H2 2025 H1 2026 Mar 2026: protocol amendment and blinded statistical review planned Oct 2024: PARASOL working group –proteinuria recommend as primary endpoint as an Dec 2023: PARASOL alternative to eGFR March 2025: FDA confirms working group proteinuria appropriate established endpoint for DMX-200 in ACTION3 study

==> picture [137 x 31] intentionally omitted <==

11

next steps

PARASOL working group conducted “ACTION3-like” population analysis of larger PARASOL observation dataset[1]

• Results of this analysis are generally consistent with the broader PARASOL analysis conducted in 2024

• Potential relationship between proteinuria at 12 months and subsequent risk of kidney failure observed that may support proteinuria as a more powerful endpoint alternative to eGFR to detect a treatment benefit of new therapies, such as DMX-200

==> picture [916 x 200] intentionally omitted <==

----- Start of picture text -----

Timing of
Assumes FDA analysis based
aligned with on protocol
endpoints and update in each
Step 1 Step 2 review process Step 3 territory Step 4
PARASOL FSGS Seek FDA alignment on Blinded review to Decision on next steps
working group 12- endpoints and process assess endpoint power towards marketing
month data analysis for blinded review, approval submission, in
received [1] ACTION3 clinical study line with commercial
protocol updates [2] partners [2,3]
~late March 2026 [2]
----- End of picture text -----

Regardless of outcome, ACTION3 study will complete full 2 year analysis for regulatory submission for potential traditional (full) approval

==> picture [137 x 31] intentionally omitted <==

1. ASX release 08 October 2025; 2. ASX release 16 March 2026 ; 3. The potential for unblinding and any accelerated (or conditional) approval submissions will be assessed based on further discussion and agreement with the appropriate regulatory authorities such as the FDA in the US

12

Competitive/complementary landscape in FSGS

==> picture [29 x 29] intentionally omitted <==

==> picture [29 x 30] intentionally omitted <==

==> picture [29 x 29] intentionally omitted <==

==> picture [32 x 22] intentionally omitted <==

Low competition in inflammatory treatment options, large unmet medical need DMX-200 is the only inflammatory modulator in development DMX-200 has potential for use in conjunction with other drugs in development if approved

==> picture [698 x 252] intentionally omitted <==

----- Start of picture text -----

Preclinical/Phase 1 AT-1 / ETA antagonist
Immune modulator
Phase 2 Novartis
atrasentan
(ERA antagonist)
Phase 3
Travere
Dimerix
sparsentan [(1)]
DMX-200
(AT1/ERA dual antagonist)
(CCR2 Inhibitor)
River3Renal
Vertex Pharma R3R01
VX-147 (ABCA1 Stimulator)
(APOL1 Inhibitor)
targets small FSGS cohort
Akebia
Boeringer Ingelheim praliciguat
BI 764198 (sGC Stimulator) Other
APOL1 inhibitor
(TRPC6 Inhibitor)
----- End of picture text -----

TRPC inhibitor

==> picture [137 x 31] intentionally omitted <==

Source: Company information and clinicaltrials.gov

13

Rare kidney disease – a potential growth market

Biopsy

FSGS diagnosis driven by rates of biopsy - growth potential as biopsy rates increase

7 per 1,000,000

Global incidence rate of FSGS per capita, per year[1]

FSGS is the most frequent primary glomerular disease that reaches end-stage renal failure in the US[2]

==> picture [57 x 57] intentionally omitted <==

DMX-200

Commercial manufacturing sites established in USA[3]

Example pricing: USA retail price for IgA Nephropathy products

==> picture [332 x 191] intentionally omitted <==

Example price for other rare kidney disease drugs per patient:

in the US (i.e. Kinpeygo/Tarpeyo in IgAN)[8] : US$15,123 per month

in the UK (Kinpeygo/Tarpeyo in IgAN)[9] : US$8,797 per month

Other key territories, including Middle East and China, use US and/or Europe as pricing reference[10]

1. Kitiyakara et al Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol. 2003 Mar;23(2):172-82. doi: 10.1053/snep.2003.50025. PMID: 12704577; 2. The United States Renal Data System (USRD), 2023 Annual Report, End Stage Renal Disease; 3. ASX investor presentation 09Mar20; 4. https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-travere-therapeutics-kidney-disorder-drug-2023-02-17/; 5. http://www.vanrafia.com; 6. Ito, et al., 2025. https://doi.org/10.1182/blood.2024025176; 7. https://endpts.com/fda-clears-traveres-rare-kidney-disease-drug-will-come-with-rems-program; 8. Micromedex Red Book (2025) Comprehensive drug pricing and product information; 9. UK list price (2025) https://www.nice.org.uk/guidance/TA937/chapter/2-information-about-targeted-release-budesonide; 10. J Mark Access Health Policy. 2016 Mar 15;4:10.3402/jmahp.v4.30458. doi: 10.3402/jmahp.v4.30458

==> picture [137 x 31] intentionally omitted <==

14

Summary of licensing deals for DMX-200 to date

==> picture [881 x 384] intentionally omitted <==

----- Start of picture text -----

Licensing deals collectively
Dimerix has successfully partnered DMX-200 across key markets valued up to
~AU$1.4 billion
1 2 3 4
in total upfront and potential
milestone fees plus royalties [1]
United States EU, CA, AU, NZ GCC, Iraq Japan
AU$48 AU$10.8 AU$0.5 AU$7.2
Over
million [1] million [2] million [3] million [4]
Upfront Upfront Upfront Upfront + 1 [st] milestone AU$65 million
in total payments received
Up to AU$892 Up to AU$219 Up to AU$120 Up to AU$100
million [1] million [2] million [3] million [4]
Milestones Milestones Milestones Milestones Significant potential additional
global deal value remains , as
Dimerix pursues and progresses
Escalating low- Escalating Between 15- licensing opportunities with
teen-low Starting at 30%
mid-teen-20% 20% potential partners outside the
twenties%
licensed territories
Royalties Royalties Royalties Royalties
----- End of picture text -----

==> picture [32 x 22] intentionally omitted <==

1. ASX release 01 May 2025; 2. Based on Euro conversions & further terms outlined in ASX Announcement on 5 October 2023; 3. Based on US dollar conversions & further terms outlined in ASX Announcement on 27 May 2024; 4. Based on Japanese ¥ Yen conversions & further terms outlined in ASX Announcement on 7 January 2025

==> picture [137 x 31] intentionally omitted <==

15

DMX-200 substantially de-risked Phase 3 renal asset

ACTION3 primary Proteinuria endpoint Commercial Study fully recruited: endpoint: proteinuria reduced risk: passed validation: 4 fixed timelines to full has potential for blinded interim commercial partners study completion in stronger statistical (futility) assessment across key territories[3] Q1 2028[4] power to resolve (March 2024)[2] DMX-200 effect[1] Passed 7 safety data Strong uptake into Indication extension: monitoring meetings open label extension DMX-200 proposed with no protocol study: indicates mechanism of action changes requested[5] patient willingness to potentially suited to continue treatment other inflammatory renal indications

==> picture [150 x 49] intentionally omitted <==

==> picture [150 x 49] intentionally omitted <==

==> picture [150 x 49] intentionally omitted <==

==> picture [137 x 31] intentionally omitted <==

1. ASX release 24 Dec 2025; 2. ASX release ASX release 11 March 2024 ; 3. ASX release 01 May 2025; 4. ASX release 15 Dec 2025; 5. ASX release 1 Nov 2025

16

Growth strategy

==> picture [818 x 161] intentionally omitted <==

Deliver ACTION3 Phase 3 Expand global commercial clinical trial partnerships • Ensure drug supply continuity and • Build on existing licensing agreements patient visits for recruited patients and relationships

• Ensure drug supply continuity and patient visits for recruited patients

• Complete recruitment of paediatric patients

• Secure additional partnerships to expand and accelerate market access

Advance pipeline development

• Identify and progress new assets in renal and/or rare disease indications

• Leverage DMX-200 platform for additional indications

• Maintain regulatory engagement (FDA, EMA, PMDA, NMPA + others)

• With partners, prepare for potential market approval and launch readiness

Grow sustainable shareholder value through clinical success, global partnerships, and pipeline diversification

==> picture [137 x 31] intentionally omitted <==

17

Corporate overview

==> picture [371 x 258] intentionally omitted <==

----- Start of picture text -----

Ticker Symbol ASX: DXB
Cash Balance (Dec25) $38.5 million
Market Capitalisation [1] $220 million
Share price [1] $0.35
Total ordinary shares on issue [1] 600,396,776
Average Daily Liquidity by value for
$0.65 million
past 30 trading days [2]
----- End of picture text -----

Research Coverage	Analyst
	Seth Lizee
	Tanushree Jain

S H A R E P R I C E

==> picture [433 x 191] intentionally omitted <==

S U B S T A N T I A L S H A R E H O L D E R S[3]

Position	Holder Name	Holding	% IC
1	Mr P Meurs	87,259,311	14.5%
TOTAL (TOP 5) Shareholders		149,412,198	24.9%

1. As at 13 March 2026; 2. Past 30 trading days liquidity as at 13 March 2026; 3. Shareholder register as at 13 March 2026 18

==> picture [12 x 540] intentionally omitted <==

==> picture [77 x 96] intentionally omitted <==

(ASX:DXB)

WELL POSITIONED TO DELIVER AGAINST STRATEGIC PLAN

ESG Statement

Dimerix is committed to integrating Environmental, Social and Governance (ESG) considerations across the development cycle of its programs, processes and decision making. The Dimerix commitment to improve its ESG performance demonstrate a strong, well-informed management attitude and a values led culture that is both alert and responsive to the challenges and opportunities of doing business responsibly and sustainably.

Dimerix HQ 425 Smith St, Fitzroy 3065 ~~Victoria, Austral~~ ia T. +61 1300 813 32119 E. investor@dimerix.com

A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus ~~on inflammatory disease treatments such as kidney and~~ respiratory diseases.

==> picture [960 x 12] intentionally omitted <==

DMX-200: unique pharmacology

• CCR2 activation promotes recruitment of inflammatory monocytes to the kidney

==> picture [33 x 32] intentionally omitted <==

• DMX-200 inhibits CCR2[1]

• Monocytes promote sclerosis and fibrosis of the kidney

==> picture [33 x 32] intentionally omitted <==

==> picture [381 x 31] intentionally omitted <==

----- Start of picture text -----

DMX-200 reduces inflammatory cells [1,2,3]
----- End of picture text -----

• Podocytes are the essential filter cells of the kidney

==> picture [445 x 195] intentionally omitted <==

----- Start of picture text -----

DMX-200 preserves podocytes [1]
MCP-1 & Angiotensin II present
Complex of CCR2 and
AT1R increases aberrant
Only MCP-1 present
signaling when both
Angiotensin II present receptors activated [1]
No ligand
in-vitro
----- End of picture text -----

==> picture [403 x 375] intentionally omitted <==

----- Start of picture text -----

500
400
300
Simultaneous inhibition of
200 * CCR2 and AT1R reduces
proteinuria an important
100
early marker of kidney
0 function [1]
Sham Vehicle DMX-200 ARB DMX-200
+ARB
200

150
Simultaneous inhibition of
100 † †
CCR2 and AT1R reduces
50 † recruitment of monocytes
to the kidney [1]
0
Sham Vehicle DMX-200 ARB DMX-200
+ARB
20
15 † Simultaneous inhibition of
10 * * * CCR2 and AT1R preserves the number of essential
5 filter cells (podocytes) in
the kidney [1]
0
Sham Vehicle DMX-200 ARB DMX-200
+ARB
Proteinuria (mg/24hours)
1
in-vivo
Macrophages, n/area
Podocytes, n/gcs
----- End of picture text -----*

==> picture [137 x 31] intentionally omitted <==

1. Ayoub MA, et al. (2015) PLoS One; doi.org/10:e0119803; 2. ASX presentation 27 October 2020; 3. Liu Y. et al (2024) Role of MCP-1 as an inflammatory biomarker in nephropathy, Front. Immunol., Sec. Inflammation doi.org/10.3389/fimmu.2023.1303076; CCR2: C-C chemokine receptor type 2; AT1R: Angiotensin II type 1 receptor; MCP1: Monocyte chemoattractant protein-1 (also known as CCL2, the ligand for CCR2); BRET: Bioluminescence Resonance Energy Transfer Assay; PCR = protein creatinine ratio; *P<0.05 vs sham STNx rats ;[† ] P<0.05 vs vehicle STNx rats;

20

DMX-200 Phase 2 effect on inflammatory biomarker[1]

Unlike other CCR2 antagonists investigated to date, treatment with DMX-200 reduces the urine concentration of the pro-inflammatory ligand of CCR2 called MCP-1[2]

==> picture [824 x 261] intentionally omitted <==

----- Start of picture text -----

Average baseline MCP-1 versus Change in MCP-1 over time on
average baseline proteinuria DMX-200 versus placebo
50% 1.5
1.0 0%
MCP-1 levels reduced
high MCP-1 correlates
-37% -39% when on
to high proteinuria DMX- 200 treatment
-50% 0.5 On placebo
On active
0.0
0 5 10 15
Time (weeks)
uMCR normalised
----- End of picture text -----

• 16 weeks treatment with DMX-200 vs placebo reduced inflammatory biomarker by 39%:

▪ DMX-200 blocks receptor responsible for inflammation

• Translates to reduced inflammation and subsequent fibrosis (scarring) in the kidney[2]

==> picture [137 x 31] intentionally omitted <==

uMCR = Urinary MCP-1 creatine ratio; PCR = protein creatinine ratio; *placebo adjusted difference 1. ASX presentation 27 October 2020; 2. Liu Y. et al (2024) Role of MCP-1 as an inflammatory biomarker in nephropathy, Front. Immunol., Sec. Inflammation doi.org/10.3389/fimmu.2023.1303076

21

PARASOL: proteinuria as an endpoint for full FDA approval

1 PARASOL FSGS Working Group 2024

==> picture [44 x 43] intentionally omitted <==

• ➢ PARASOL was formed in Dec-23 to address the need to validate alternative surrogate endpoints for FSGS, and is a coalition of nonprofit organizations, academia, registries, trials and Sponsors to share data to support analysis[(1)]

• PARASOL confirmed that eGFR slope is a valid endpoint for predicting progression of kidney disease

• It is recognised FSGS patients see higher proteinuria, even in remission, due to residual scaring of the glomeruli

• PARASOL data demonstrated the strong relationship between a reduction in proteinuria and a reduction in the progression of kidney disease in FSGS patients l for FSGS

2

Biological Plausibility

==> picture [44 x 43] intentionally omitted <==

  - ➢ The FDA has emphasised the need for programs wishing to use proteinuria endpoints to be able to justify the biological plausibility (scientific rationale of why or how the drug candidate is having the desired effect) of the drug on the endpoint chosen

• Dimerix has existing preclinical evidence on the preservation effect of DMX-200 on the specialist cells on the kidney – the podocytes[2]

• Dimerix has existing clinical and preclinical evidence of reduced recruitment of monocytes to the kidney and reduced MCP-1 levels

• Reduction in proteinuria is now a validated endpoint for full FDA approval

• PARASOL has increased the range of potential endpoints that may best show the treatment effect of DMX-200

3

==> picture [437 x 13] intentionally omitted <==

----- Start of picture text -----

ACTION3 capturing all proposed endpoint data: eGFR and proteinuria
----- End of picture text -----

==> picture [130 x 62] intentionally omitted <==

Proteinuria

• Randomised, double blind PCR values over 24 months

• PCR captured across 4-week washout

• PCR measured over additional 24 month open-label period

==> picture [130 x 63] intentionally omitted <==

==> picture [130 x 63] intentionally omitted <==

eGFR slope

Other endpoints

• Randomised, double blind eGFR values captured over 24 • Classical definitions of complete and partial remission months, including raw values and total eGFR slope • PARASOL-informed response endpoints • Hard-renal endpoints (where available)

==> picture [137 x 31] intentionally omitted <==

1. Coalition made up of: NephCure, ISGD, NKF, KHI are co-sponsors of the project, FDA and EMA involvement, University of Michigan is data

coordinating center, Industry invited as participants; 2.

22

Intellectual property portfolio

DMX-200

==> picture [38 x 61] intentionally omitted <==

==> picture [38 x 61] intentionally omitted <==

Exclusivity Portfolio 3 7/10 years Exp.2042 Orphan exclusivity from (if granted) marketing approval date Formulation Portfolio 5 in many territories[1] Portfolio 2 Global application[3] + Exp.2045/6 Exp.2042 (if granted) Paediatric (if granted) exclusivity period Portfolio 1 Method of Use & Formulation Portfolio 4 Method of Use Provisional application[4] extension[1] Global application[3] Exp.2044 Exp.2032 (if granted) (2033 in US) Method of Use & Formulation Trademarks Method of Use Global application[3] Various trademarks Granted in key territories[2] Global applications

==> picture [137 x 31] intentionally omitted <==

1. DMX-200 is a “New Chemical Entity: an active moiety not previously approved, which can attract exclusivity periods in various territories; 2. Granted patents US9,314,450, US10,058,555, US10,525,038, US11,382,896, US12,083,102, CN2012800046165, CA2,821,985, EP12734251.7, HK 1404477.8, IL227414, JP2013-547780, 23 SA2013/5897, AU2012206945; 3. Patent applications: PCT/AU2022/050013, PCT/AU2022/050249 and PCT/AU2024/050416; 4. US Provisional Application 63/887,984

Dimerix board

==> picture [106 x 106] intentionally omitted <==

==> picture [157 x 81] intentionally omitted <==

Previous experience:

==> picture [36 x 15] intentionally omitted <==

==> picture [43 x 18] intentionally omitted <==

(Faulding)[(1)]

• Senior pharmaceutical executive with a demonstrated record of achievement and leadership over more than 30 years within the pharmaceutical and biotechnology industries

• Significant accomplishments in capital raising initiatives, pipeline development and licensing

• ✓ BSc ~~−~~ Chemistry

• ✓ MBA ~~−~~ Business

==> picture [106 x 106] intentionally omitted <==

==> picture [157 x 81] intentionally omitted <==

Previous experience:

==> picture [17 x 17] intentionally omitted <==

(2)

==> picture [37 x 8] intentionally omitted <==

• Experienced in product development, commercial strategy development & execution

• Successfully commercialized pharmaceutical products globally

• ✓ BSc (Hons) ~~−~~ Pharmacology

• ✓ PhD ~~−~~ Pharmaceutics

• ✓ MBA ~~−~~ Business

• ✓ M.IP.Law ~~−~~ Intellectual Property Law

==> picture [106 x 106] intentionally omitted <==

==> picture [157 x 82] intentionally omitted <==

Previous experience:

==> picture [18 x 17] intentionally omitted <==

(1)

==> picture [39 x 13] intentionally omitted <==

==> picture [41 x 11] intentionally omitted <==

• Extensive biotech drug development & commercial manufacturing experience

• Responsible for successful global commercialization programs & NDA registrations

• ✓ BSc (Hons) ~~−~~ Chemistry

• ✓ MBA ~~−~~ Business

==> picture [106 x 106] intentionally omitted <==

==> picture [157 x 82] intentionally omitted <==

Previous experience:

==> picture [31 x 16] intentionally omitted <==

==> picture [36 x 12] intentionally omitted <==

==> picture [24 x 12] intentionally omitted <==

==> picture [41 x 8] intentionally omitted <==

• Experienced executive in pharmaceutical operations

• Background in small molecules development and analytical development

• ✓ BSc (Hons) ~~−~~ Chemistry

• ✓ PhD ~~–~~ Industrial Chemistry

==> picture [106 x 106] intentionally omitted <==

==> picture [156 x 82] intentionally omitted <==

Previous experience:

==> picture [40 x 18] intentionally omitted <==

==> picture [51 x 16] intentionally omitted <==

==> picture [42 x 14] intentionally omitted <==

• Experienced technology and governance professional with a focus in operations, risk management, assurance, and AI

• Provides advisory services to a family office with multiple Australian biotech investments

• ✓ BEng (Hons) ~~−~~ Chemical Engineering

• ✓ BCom ~~−~~ Commerce

==> picture [137 x 31] intentionally omitted <==

1. Acquired by Pfizer in 2015; 2. Acquired by Pfizer in 2009

24

Dimerix management

==> picture [95 x 95] intentionally omitted <==

==> picture [157 x 76] intentionally omitted <==

Previous experience:

==> picture [17 x 18] intentionally omitted <==

(1)

==> picture [37 x 7] intentionally omitted <==

• Experienced in product development, commercial strategy development & execution

• Successfully commercialised multiple pharmaceutical products

• ✓ BSc (Hons) ~~−~~ Pharmacology

• ✓ PhD ~~−~~ Pharmaceutics

• ✓ MBA ~~−~~ Business

• ✓ M.IP.Law ~~−~~ Intellectual Property Law

==> picture [94 x 95] intentionally omitted <==

==> picture [157 x 76] intentionally omitted <==

Previous experience:

==> picture [28 x 18] intentionally omitted <==

==> picture [41 x 16] intentionally omitted <==

==> picture [47 x 12] intentionally omitted <==

• Experienced finance and governance executive with extensive experience of both ASX ~~-~~

• and NASDAQ listed companies.

• Brings more than 30 years’ international finance leadership experience across Australia, US, Canada, the UK and Hong Kong.

• ✓ BSc (Hons) ~~–~~ Business Studies

• ✓ MAICD

• ✓ Chartered Accountant

==> picture [95 x 95] intentionally omitted <==

==> picture [157 x 76] intentionally omitted <==

Previous experience:

==> picture [29 x 13] intentionally omitted <==

==> picture [38 x 9] intentionally omitted <==

==> picture [38 x 8] intentionally omitted <==

• 35 years international experience in drug development, commercialization and corporate leadership

• ~~-~~

• Planning, Financing, Pre clinical, Clinical Development, Regulatory Approval, Product Launch, Pharmacovigilance, and Medical Affairs

• ✓ B.Pharm (Hons) ~~-~~ Pharmacy

• ✓ MBBS ~~-~~ Medicine and Surgery

==> picture [95 x 95] intentionally omitted <==

==> picture [157 x 76] intentionally omitted <==

Previous experience:

==> picture [35 x 22] intentionally omitted <==

• Experienced pharmaceutical executive in project management, clinical development and research translation

• BD and strategic alliance leader

• Led multidisciplinary R&D&C teams for 13 years

• ✓ BSc (Hons) ~~–~~ Genetics

• ✓ PhD ~~–~~ Molecular Immunology

• ✓ MBA ~~–~~ Business & Leadership

==> picture [137 x 31] intentionally omitted <==

1. Acquired by Pfizer in 2009;

25

Medical Advisory Board

==> picture [105 x 106] intentionally omitted <==

==> picture [97 x 106] intentionally omitted <==

==> picture [105 x 106] intentionally omitted <==

==> picture [106 x 106] intentionally omitted <==

==> picture [106 x 106] intentionally omitted <==

==> picture [107 x 106] intentionally omitted <==

==> picture [106 x 106] intentionally omitted <==

==> picture [928 x 85] intentionally omitted <==

Professor of Clinical Trials and Professor of Medicine & Personalized Medicine: Molecular & Cellular University Medical Center Pharmacology: University of Groningen, the Netherlands. Miami. Chief of the Katz He specializes in the research Family Division of Nephrology of novel treatment and Hypertension. She has an approaches to slow the onset extensive history of of diabetic cardiovascular and translational excellence for renal disease. Hiddo has been patients with renal disease instrumental in interactions and has uncovered novel between industry, researchers pathogenetic mechanisms and regulatory agencies in the and therapeutic approaches validation of surrogate for glomerular disorders. endpoints for renal trials.

Mayer Professor of Renal Medicine: Department of Cardiovascular Sciences; University of Leicester and Nephrologist. Jonathan is the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases (RaDaR) and a member of the steering committee for the International IgA Nephropathy Network.

An attending physician and Director of the Kidney and Blood Pressure Center in the Division of Nephrology at Tufts Medical Center. Lesley’s major research interest is in the estimation and measurement of glomerular filtration rate (GFR) and in defining alternative endpoints for CKD progression trials based on GFR decline and changes in albuminuria.

Renal Physician and Head of the Renal Clinical trials at the Royal North Shore hospital, Sydney, Australia. Muh Geot’s main areas of research are in understanding the mechanisms of kidney fibrosis, biomarkers research, and identifying strategies in delaying progressive kidney disease including glomerular diseases.

Graduated from Haverford College and the University of Pennsylvania School of Medicine. He has been a practicing pediatric nephrologist for 35 years. Has been the PI of NIDDK and industry sponsored clinical trials in glomerular disease and am a Co ~~-~~ Investigator in the NEPTUNE and CureGN observational cohort studies.

Assistant Professor in the Division of Nephrology at the University of Michigan. Interest in observational studies in glomerular disease, including NEPTUNE and CureGN. Lead on PARASOL program to define FSGS endpoints with by applying statistical methods for clinical outcome definition and prediction of kidney disease progression.

==> picture [137 x 31] intentionally omitted <==

26